Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrylammonium SCHEMBL19811267 | 0.75 | TSHR (0.33) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| SCHEMBL17710323 | 0.74 | CA2 (0.38) | TSHR | |
| SCHEMBL23360809 | 0.72 | NR1I2 (0.41) | TSHRNFKB1 | |
| Tetrylammonium SCHEMBL36703 | 0.71 | TSHR (0.57) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| SCHEMBL11223474 | 0.71 | RECQL (0.44) | TSHRNFKB1 | |
| Tetrylammonium SCHEMBL1462858 | 0.71 | — | — | |
| SCHEMBL9929755 | 0.69 | CA2 (0.34) | TSHRNFKB1 | |
| Tetrylammonium SCHEMBL3643964 | 0.69 | TSHR (0.53) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL331297 | 0.69 | TSHR (0.53) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL28602156 | 0.69 | TSHR (0.53) | TSHRNFKB1KCNA1KDM4EPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642778-B2 | Ionic liquids | MERCK PATENT GMBH (DE) | 2014-02-04 | — | — | US | disclosed |
| EP-2279192-B1 | IONIC LIQUIDS | MERCK PATENT GMBH (DE) | 2013-10-30 | — | — | EP | disclosed |
| US-20110152537-A1 | IONIC LIQUIDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-23 | — | — | US | disclosed |
| EP-2279192-A2 | IONIC LIQUIDS | Merck Patent GmbH (DE) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009152902-A2 | IONIC LIQUIDS | MERCK PATENT GMBH, (DE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152537-A1 | IONIC LIQUIDS | HCN3, CHRNA3, CHRM3 | TSHR 800/4885NFKB1 4287/4885KCNA1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.